eligibility_summary
Eligible: 18–75, EBV+ T‑cell lymphoma with measurable disease, HLA‑A0201/1101/2402/0203 (≥1) and semi‑matched donor, tumor tissue for neoantigen seq, failed prior systemic tx, ECOG 0–1, adequate organs (LVEF≥50%), acceptable infection screen, life ≥6 mo, contraception, washout done. Exclude: pregnancy, severe allergy, organ transplant or allo‑HSCT/GVHD, CNS involvement, active autoimmune, uncontrolled infection, major organ/pulmonary/CV disease, uncontrolled HTN, high‑dose steroids/immunosuppressants, antigen‑pathway gene defects, recent other malignancy, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06224049 tests hNeo‑T, a targeted haploidentical neoantigen T‑cell therapy (cellular immunotherapy), for relapsed/refractory EBV‑positive T‑cell lymphoma. Donor PBMCs (≥50% HLA match, HLA‑A02/11/24 alleles) are used to generate ex vivo–expanded T cells primed to patient‑specific tumor neoantigens. After infusion, these cytotoxic T cells recognize neoantigen peptides on MHC class I of malignant T cells via TCRs and eliminate them through perforin/granzyme mechanisms. Optional lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog) is used to enhance engraftment/persistence by reducing host lymphocytes. Targets/pathways: EBV‑positive malignant T cells displaying tumor neoantigens, antigen presentation (HLA‑A class I), TCR signaling, and downstream cytotoxic effector pathways. Dose levels: 5×10^7 or 1×10^8 cells.